Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Lucemyra (lofexidine) is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Lofexidine vs. Clonidine for Opioid Withdrawal: Lofexidine significantly reduced opioid withdrawal symptom severity in one study compared to clonidine, but four other studies showed no significant difference. No significant difference in detoxification completion rates was observed between the two drugs.
• Lofexidine vs. Methadone and Buprenorphine: Lofexidine was equally effective in controlling withdrawal symptoms when compared to methadone and buprenorphine, with a better side effect profile.
• Lofexidine for Stress Management in OUD: Preliminary results suggest that lofexidine may improve treatment outcomes by targeting stress in individuals with opioid use disorder.
• Lofexidine was associated with significant adverse effects, including hypotension, bradycardia, orthostasis, somnolence, sedation, dry mouth, rebound elevations in blood pressure, and QT interval prolongation. It is contraindicated in patients taking beta-blockers and ACE inhibitors.
• In comparison to clonidine, lofexidine caused fewer adverse effects, though it still resulted in significant hypotension, bradycardia, and pupillary constriction in one study.
• There is no population type or subgroup information available in the reviewed studies.